ClinicalTrials.gg
CompletedNCT00473460Updated Oct 28, 2014

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Placebo in Lung Diseases and Bronchitis, Chronic, sponsored by Bayer. Completed at 78 sites in 15 countries. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-10-28.

Primary conditionBronchitis, ChronicRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bronchitis, Chronic
Why
  1. The study's listed conditions name Bronchitis, Chronic, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,404
Allocation
Randomized
Ages
45 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies in Bronchitis, Chronic with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Bronchitis, Chronic · United States.

Enrollment
6th of 82
1,404 · median 126
Started
2004
with 5 others
Phase 3
19 of 100
none open now
Registered
25th of 100
by date

Among the 100 studies in Bronchitis, Chronic with a site in United States, this one is the 6th largest by enrollment of the 82 interventional ones that give a count, is one of 6 that started in 2004, is one of 19 in phase 3, and was the 25th registered.

Bronchitis, Chronic

209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.

Browse Bronchitis, Chronic studies →

Open to participants now

7 of the 100 studies in Bronchitis, Chronic with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Bronchitis, Chronic studies recruiting now, 5 (50%) set no upper age limit and 2 (20%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 45 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Bronchitis, Chronic with a site in United States, or all of them as a file.
02

Study summary

Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine if this drug, when taken periodically in addition to the patients normal treatment, is effective at reducing the number of flare-ups of chronic bronchitis he has. Approximately 1132 subjects will participate, and it is expected that the study will run for 2 years in order to reach that goal. The patients individual involvement in the study will be 17 months. Moxifloxacin will be compared to a placebo drug (no active ingredients). The study medication (moxifloxacin or placebo) will be taken in addition to the patients normal medication for chronic bronchitis. In addition to the first clinic visit, called a screening visit, the patient will be required to come back to the clinic for ten more study visits, every 8 weeks. At the first visit the study co-ordinator will provide him with the dates for all the visits. Over a period of 48 weeks the patient will return to the clinic on 6 occasions where he will receive the study medication which he will take for five days, in addition to his normal treatment for chronic bronchitis. After this time the patient will enter a follow up period for 24 weeks, where he will come to the clinic for assessments and continue to take his normal medication but not receive the study drug. A complete medical history will be taken at the first visit, including the patients past and current smoking habit. A breath test will be performed to assess how well his lungs are functioning. In addition, he will also be asked to provide a sputum sample for a microbiological examination to identify any bacteria present in the sample. The patient must be able to provide a sputum sample at the screening visit. If the patient meets all the inclusion / exclusion criteria for the study, he will be allocated randomly to one of the following treatment groups at the second visit.- Treatment group 1: Receives moxifloxacin orally once daily for five days.- Treatment group 2: Receives a matching placebo once daily for five days.In between each visit (four weeks after your clinic visit), the study site co-ordinator will contact the patient to check on his well being. If the patient or the doctor decides to stop the patients participation in the trial for any reason, the patient will be required to return to the clinic for a physical examination, take a breath test, provide a sputum sample (if possible) and have a blood sample taken.

03

Conditions studied

  • Lung Diseases
  • Bronchitis, Chronic

Browse trials for

Keywords

  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Acute exacerbation of chronic bronchitis
  • Prevention therapy
  • Antibiotics
  • Fluoroquinolone
  • Moxifloxacin
  • AECB
04

In context

Bronchitis, Chronic Reclassified

209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.

This study's enrollment of 1,404 is above the median of 101 across 154 interventional studies indexed under Bronchitis, Chronic.

Browse Bronchitis, Chronic studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Compared within Bronchitis, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
45 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female out-patients >/= 45 years
  • Subjects suffering from chronic bronchitis
  • \</= 70% and FEV1/FVC \</= 70% predicted from age, height and sex
  • No documented episode of AECB (requiring treatment) within 6 weeks of randomization and not experiencing an exacerbation at the time of screening
  • Sputum production on most days, even when exacerbation free
  • Subjects presented with at least two documented (i.e. requiring antibiotics and/or systemic administration) acute exacerbation episodes during the last 12 monthsIf receiving chronic therapy with inhaled long acting bronchodilators and/or inhaled or systemic steroids, the treatment must have remained stable for the preceding 6 weeks prior to screening
  • Smoking history of at least 20 pack-years
  • Subjects willing and able to give fully informed written consent

Exclusion criteria

Exclusion Criteria:

  • Subjects with to moxifloxacin- Known bronchial carcinoma, pulmonary tuberculosis, cystic fibrosis, documented chronic bronchial asthma or diffuse bronchiectasis- Subjects who are actively participating in intensive pulmonary rehabilitation programs
  • Subjects with a known history of chronic colonization of pathogenic organisms resistant to moxifloxacin, e.g. Pseudomonas spp, MRSA
  • No systemic or inhaled antibiotic therapy during the 6 weeks prior to screening and any long term antibiotic usage
  • Subjects requiring home ventilatory support for and those who have a tracheostomy in situ (subjects requiring home/potable oxygen therapy or CPAP for sleep apnea can be included)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,404 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Avelox (Moxifloxacin, BAY12-8039)

  • Placebo comparator
    Arm 2

    Drug: Placebo

Interventions

  • Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks

  • DrugPlacebo

    Matching placebo capsules orally once daily for 5 days every 8 weeks.

07

What researchers measure

Primary outcomes

  1. Number of exacerbations after 48 weeks of intermittent pulse treatment

    Time frame: After 48 weeks of treatment

Secondary outcomes

  1. Impact of treatment on the health related Quality of Life in St. George's Respiratory Questionaire (SGRQ) scores

    Time frame: At week 48

  2. Deterioration in lung function test (PFEV1)

    Time frame: At week 48

  3. Frequency of hospitalisation

    Time frame: At week 48

  4. Mortality rates

    Time frame: At week 48

  5. Time of first exacerbation

    Time frame: Through to week 48

  6. Frequency of acute exacerbation of chronic bronchitis

    Time frame: At week 24 and 72 (end of follow-up)

  7. Time to next exacerbation from last pulsed dose

    Time frame: At week 48

  8. Length of exacerbations

    Time frame: Through to week 48

  9. Percentage of exacerbation free time

    Time frame: Through to week 48

08

Study locations

78 sites
  • Tucson, Arizona 85723, United States
  • Long Beach, California 90822-5201, United States
  • Los Angeles, California 90073-1003, United States
  • Bay Pines, Florida 33744, United States
  • Kansas City, Missouri 64128-2295, United States
  • Buffalo, New York 14215-1129, United States
  • Dallas, Texas 75216-7167, United States
  • Houston, Texas 77024, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78284-5799, United States
  • Richmond, Virginia 23249-0002, United States
  • Escaldes - Engordany, Andorra
  • Florencio Varela, Buenos Aires 1888, Argentina
  • Buenos Aires, Capital Federal 1416, Argentina
  • Buenos Aires, Capital Federal 1426, Argentina
  • Buenos Aires, Capital Federal C1120AAF, Argentina
  • Juiz de Fora, MG 36036-110, Brazil
  • Porto Alegre, RS 90610-000, Brazil
  • Sao Paulo, SP 04023-900, Brazil
  • Sao Paulo, SP 05403-900, Brazil
  • Santiago, Chile
  • Valparaiso, 236-3058, Chile
  • Arras, 62000, France
  • Mont-de-marsan, 40000, France
  • Nice, 06000, France
  • Orthez, 64300, France
  • Rosiers D'egletons, 19300, France
  • Strasbourg, 67000, France
  • Kaufbeuren, Bayern 87600, Germany
  • Gelnhausen, Hessen 63571, Germany
  • Hannover, Niedersachsen 30159, Germany
  • Rotenburg, Niedersachsen 27356, Germany
  • Witten, Nordrhein-Westfalen 58452, Germany
  • Neuwied, Rheinland-Pfalz 56564, Germany
  • Bad Segeberg, Schleswig-Holstein 23795, Germany
  • Berlin, 10717, Germany
  • Berlin, 10969, Germany
  • Berlin, 12043, Germany
  • Hamburg, 20535, Germany
  • Rio, Patras 265 04, Greece
  • Athens, 11527, Greece
  • Dublin, 8, Ireland
  • Dublin, DUBLIN 7, Ireland
  • Afula, 18101, Israel
  • Ashkelon, 78306, Israel
  • Bat Yam, 59512, Israel
  • Tel Aviv, 64239, Israel
  • Ferrara, 44100, Italy
  • Milano, 20123, Italy
  • Milano, 20157, Italy
  • Pavia, 27100, Italy
  • Guadalajara, Jalisco 44280, Mexico
  • Mérida, Yucatán 97001, Mexico
  • Mérida, Yucatán 97070, Mexico
  • Chihuahua, 31350, Mexico
  • Bloemfontein, Free State 9300, South Africa
  • Bloemfontein, Free State 9301, South Africa
  • Johannesburg, Gauteng 2057, South Africa
  • Pretoria, Gauteng 0040, South Africa
  • Pretoria, Gauteng 0157, South Africa
  • Durban, KwaZulu Natal 4091, South Africa
  • Cape Town, Western Cape 7531, South Africa
  • Cape Town, Western Cape 7569, South Africa
  • Paarl, Western Cape 7646, South Africa
  • Badalona, Barcelona 08916, Spain
  • Ronda, Málaga 29400, Spain
  • Barcelona, 08036, Spain
  • Madrid, 28040, Spain
  • Valencia, 46009, Spain
  • Valladolid, 47010, Spain
  • Bristol, Avon BS10 5NB, United Kingdom
  • London, Greater London E1 2AT, United Kingdom
  • London, Greater London E2 9JX, United Kingdom
  • London, Greater London NW3 2QG, United Kingdom
  • London, Greater London SW17 0QT, United Kingdom
  • London, Greater London SW3 6NP, United Kingdom
  • Birmingham, West Midlands B15 2TH, United Kingdom
  • Leeds, West Yorkshire LS9 7TF, United Kingdom
09

References and documents

Publications

  • Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, Wilson R; PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010 Jan 28;11(1):10. doi: 10.1186/1465-9921-11-10. Erratum In: Respir Res. 2010;11:88. PubMed 20109213 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2007
First posted
May 15, 2007
Start
Oct 2004
Primary completionActual
Jan 2007
CompletionActual
Jan 2007
Last update
Oct 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00473460
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 15, 2007
Start date
Oct 2004
Primary completion
Jan 2007
Completion
Jan 2007
Last update
Oct 28, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion